Horizon Discovery Group has entered an agreement to acquire Sage Labs Inc. for as much as $16 million in cash and $32 million through the issue of new shares. Sage generates advanced in vivo transgenic disease models for use in preclinical research, which builds on Horizon’s acquisition of CombinatoRx in July, positioning the company among the leading gene-editing companies and provider of services at all stages of translational genomics and personalized medicine research from sequence to treatm...